Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg weekly) significantly improve pain and function in patients with obesity and moderate-to-severe knee osteoarthritis, achieving clinical benefits comparable to or exceeding standard therapies like NSAIDs and physical therapy.
If you have knee osteoarthritis and a BMI over 30, GLP-1 medications like semaglutide (2.4 mg weekly) can significantly reduce pain and improve function, potentially delaying or avoiding surgery. This works not just by helping you lose weight, but by directly reducing inflammation in the joint. Current guidelines suggest aiming for more than 7-10% weight loss for maximum benefit, which these drugs help achieve more effectively than lifestyle changes alone for many people.
By week 68, patients in the treatment arm achieved an average 13.7% weight loss... The Western Ontario and McMaster Universities Osteoarthritis Index pain scores improved by 41.7 points... in the semaglutide group... yielding a difference of 14.1 points (p<0.001)... Such improvements are comparable to or exceed those reported with widely accepted OA therapies, including non- steroidal anti- inflammatory drugs (NSAIDs), structured physical therapy programmes and intra- articular injections.
Why this rating
Supported by a large, multi-center randomized controlled trial (STEP 9) and corroborated by observational cohort data, though long-term structural data is still emerging.
Source
If the evidence is there, why are GLP-1 receptor agonists not on-label for hip and knee osteoarthritis in overweight patients?
Francesco Ursini et al. · RMD Open · 2025
DOI 10.1136/rmdopen-2025-006025
More from this paper
- GLP-1 receptor agonists (specifically liraglutide) exert direct anti-inflammatory and chondroprotective effects in osteoarthritis by suppressing NF-κB activation, reducing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), and downregulating cartilage-degrading enzymes (MMPs, ADAMTS), while promoting type II collagen synthesis.Moderate
- GLP-1 receptor agonists reduce the incidence of knee surgeries and slow cartilage loss in patients with knee osteoarthritis and type 2 diabetes, as demonstrated in real-world observational cohorts.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →